Table 2 The AUC analysis for prediction of in-hospital mortality and clinical worsening.
AUC (95%CI) | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | Cut-off value | |
|---|---|---|---|---|---|---|
In-hospital mortality | ||||||
IMPROVE‡ | 0.96 (0.90–0.99) | 89 (75–97) | 96 (87–100) | 94 (81–99) | 93 (82–98) | > 2 |
IMPROVE-DD‡ | 0.96 (0.90–0.99) | 87 (72–96) | 96 (87–100) | 94 (80–99) | 91 (80–97) | > 4 |
D-dimer | 0.88 (0.80–0.94) | 89 (75–97) | 75 (60–86) | 72 (57–84) | 91 (77–97) | > 1.3 μg/mL |
APACHE II*†‡ | 0.70 (0.59–0.79) | 84 (69–94) | 49 (35–63) | 55 (42–68) | 81 (63–93) | > 7 |
Charlson comorbidity index*†‡ | 0.70 (0.59–0.79) | 53 (36–69) | 82 (69–92) | 69 (49–85) | 70 (57–81) | > 2 |
SpO2*† | 0.74 (0.63–0.82) | 58 (41–74) | 80 (67–90) | 69 (50–84) | 72 (59–83) | ≤ 79% |
Clinical worsening | ||||||
IMPROVE | 0.80 (0.70–0.88) | 60 (47–74) | 94 (80–99) | 94 (81–99) | 59 (44–72) | > 2 |
IMPROVE-DD | 0.79 (0.69–0.87) | 71 (58–83) | 82 (65–93) | 87 (74–95) | 63 (47–77) | > 3 |
D-dimer | 0.74 (0.64–0.83) | 70 (56–81) | 73 (55–87) | 81 (67–91) | 59 (42–74) | > 1.27 μg/mL |
APACHE II | 0.71 (0.60–0.80) | 55 (42–68) | 80 (61–92) | 84 (69–94) | 48 (34–63) | > 10 |
Charlson comorbidity index* | 0.68 (0.57–0.78) | 46 (33–60) | 91 (76–98) | 90 (73–98) | 50 (37–63) | > 2 |
SpO2 | 0.79 (0.70–0.87) | 63 (49–75) | 91 (76–98) | 92 (79–98) | 59 (44–72) | ≤ 81% |
